Merck (MRK) to Acquire Idenix Pharma (IDIX) for $24.50/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
JMP Securities Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Market Perform
June 9, 2014 1:00 PM EDTJMP Securities upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Market Underperform to Market Perform.
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $7.23 yesterday.
... MoreBaird Upgrades Idenix Pharmaceuticals (IDIX) to Neutral on Takeover
June 9, 2014 10:35 AM EDTBaird upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Underperform to Neutral with a price target of $24.00 (from $3.00).
Analyst Brian Skorney comments, "Merck's $3.85 billion bid for Idenix (a 230%+ premium) is, on the surface, an acquisition of an early stage set of Hep C... More
Gilead Sciences (GILD): Analyst Comments on Increased Merck (MRK) Competition (ABBV)
June 9, 2014 9:17 AM EDTAnalyst Robyn Karnauskas of Deutsche Bank commented on impact to Gilead Sciences (NASDAQ: GILD) from potential competition from Merck (NYSE: MRK). Earlier Merck announced it plans to acquire Idenix (Nasdaq: IDIX).
"We have already modeled in competition to the Gilead franchise with Merck initially entering the market in late 15/16. We... More
Merck (MRK) Says First Patient Enrolled in Ph-3 Trial of ISENTRESS
June 5, 2014 5:03 PM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the companys global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. ISENTRESS film-coated tablets are currently... More
